title: Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study.
abstract: BACKGROUND
  A secondary end point of the NBL90 protocol (Rubie H et al. Pediatr Oncol 2001;36:247-250) was the concern in this infant population for possible carboplatin-(CBDCA) induced late side effects including impaired renal and hearing functions.
  
  
  METHODS
  Glomerular filtration rate (GFR), tubular function (TF), pure tone audiometry (PTA), high-frequency, and transient evoked-otoacoustic emission were prospectively assessed in 30 children alive and disease-free 6 years after the end of the treatment.
  
  
  RESULTS
  Median age at diagnosis and at assessment was 4.7 months and 7 years, respectively. Blood pressure was < or =97.5 centile in all children. The mean estimated GFR was 114 +/- 13 ml/min/1.73 m(2) by Schwartz formula [range 87-145]. TF assessment failed to demonstrate any impairment. 29/30 children had grade 0 ototoxicity and all transient evoked otoacoustic emission were normal.
  
  
  CONCLUSIONS
  With a 6-year follow-up the combination of VP16 and carboplatin given at conventional doses is safe on renal and hearing functions in infants with unresectable neuroblastomas treated according to SFOP NB90.
authors.affiliation: Centre Léon Bérard, Département de Pédiatrie, 69373 Lyon Cedex, France. bergeron@lyon.fnclcc.fr
authors.forename: C
authors.initials: C
authors.lastname: Bergeron
authors.forename: L
authors.initials: L
authors.lastname: Dubourg
authors.forename: P
authors.initials: P
authors.lastname: Chastagner
authors.forename: F
authors.initials: F
authors.lastname: Mechinaud
authors.forename: E
authors.initials: E
authors.lastname: Plouvier
authors.forename: A S
authors.initials: AS
authors.lastname: Desfachelles
authors.forename: F
authors.initials: F
authors.lastname: Dusol
authors.forename: B
authors.initials: B
authors.lastname: Pautard
authors.forename: C
authors.initials: C
authors.lastname: Edan
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
authors.forename: P
authors.initials: P
authors.lastname: Froehlich
authors.forename: H
authors.initials: H
authors.lastname: Rubie
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols; D016190:Carboplatin / Q000009:adverse effects*; D005260:Female; D005602:France / Q000453:epidemiology; D034381:Hearing Loss / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000139:chemically induced* / Q000453:epidemiology; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin